These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16606445)

  • 1. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver.
    Di Gioia S; Bianchi P; Destro A; Grizzi F; Malesci A; Laghi L; Levrero M; Morabito A; Roncalli M
    BMC Cancer; 2006 Apr; 6():89. PubMed ID: 16606445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma.
    Macheiner D; Heller G; Kappel S; Bichler C; Stättner S; Ziegler B; Kandioler D; Wrba F; Schulte-Hermann R; Zöchbauer-Müller S; Grasl-Kraupp B
    J Hepatol; 2006 Jul; 45(1):81-9. PubMed ID: 16516329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
    Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma.
    Schagdarsurengin U; Wilkens L; Steinemann D; Flemming P; Kreipe HH; Pfeifer GP; Schlegelberger B; Dammann R
    Oncogene; 2003 Mar; 22(12):1866-71. PubMed ID: 12660822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian Patients.
    Araújo OC; Rosa AS; Fernandes A; Niel C; Villela-Nogueira CA; Pannain V; Araujo NM
    PLoS One; 2016; 11(4):e0153796. PubMed ID: 27078152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonality of nodular lesions in liver cirrhosis and chromosomal abnormalities in monoclonal nodules of altered hepatocytes.
    Gong L; Li YH; Su Q; Chu X; Zhang W
    Histopathology; 2010 Apr; 56(5):589-99. PubMed ID: 20459569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis.
    Lee S; Lee HJ; Kim JH; Lee HS; Jang JJ; Kang GH
    Am J Pathol; 2003 Oct; 163(4):1371-8. PubMed ID: 14507645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors.
    Nakamura N; Carney JA; Jin L; Kajita S; Pallares J; Zhang H; Qian X; Sebo TJ; Erickson LA; Lloyd RV
    Lab Invest; 2005 Sep; 85(9):1065-75. PubMed ID: 15980887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis.
    Yu J; Ni M; Xu J; Zhang H; Gao B; Gu J; Chen J; Zhang L; Wu M; Zhen S; Zhu J
    BMC Cancer; 2002 Nov; 2():29. PubMed ID: 12433278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.
    Zhong S; Yeo W; Tang MW; Wong N; Lai PB; Johnson PJ
    Clin Cancer Res; 2003 Aug; 9(9):3376-82. PubMed ID: 12960125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation.
    Zekri Ael-R; Nassar AA; El-Din El-Rouby MN; Shousha HI; Barakat AB; El-Desouky ED; Zayed NA; Ahmed OS; El-Din Youssef AS; Kaseb AO; Abd El-Aziz AO; Bahnassy AA
    Asian Pac J Cancer Prev; 2014 Jan; 14(11):6721-6. PubMed ID: 24377595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
    Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
    JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
    Calvisi DF; Ladu S; Gorden A; Farina M; Conner EA; Lee JS; Factor VM; Thorgeirsson SS
    Gastroenterology; 2006 Apr; 130(4):1117-28. PubMed ID: 16618406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs.
    Lorente A; Mueller W; Urdangarín E; Lázcoz P; Lass U; von Deimling A; Castresana JS
    Brain Pathol; 2009 Apr; 19(2):279-92. PubMed ID: 18616639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis.
    Um TH; Kim H; Oh BK; Kim MS; Kim KS; Jung G; Park YN
    J Hepatol; 2011 May; 54(5):939-47. PubMed ID: 21145824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
    Ahn EY; Kim JS; Kim GJ; Park YN
    Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma.
    Geli J; Kiss N; Lanner F; Foukakis T; Natalishvili N; Larsson O; Kogner P; Höög A; Clark GJ; Ekström TJ; Bäckdahl M; Farnebo F; Larsson C
    Endocr Relat Cancer; 2007 Mar; 14(1):125-34. PubMed ID: 17395981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma.
    Lendvai G; Szekerczés T; Gyöngyösi B; Schlachter K; Kontsek E; Pesti A; Patonai A; Werling K; Kovalszky I; Schaff Z; Kiss A
    Pathol Oncol Res; 2019 Jul; 25(3):1103-1109. PubMed ID: 30411298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A.
    Macheiner D; Gauglhofer C; Rodgarkia-Dara C; Grusch M; Brachner A; Bichler C; Kandioler D; Sutterlüty H; Mikulits W; Schulte-Hermann R; Grasl-Kraupp B
    Cancer Res; 2009 Jan; 69(1):235-42. PubMed ID: 19118008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of RASSF1A hypermethylation with risk of HBV/HCV-induced hepatocellular carcinoma: A meta-analysis.
    Peng JL; Wu JZ; Li GJ; Wu JL; Xi YM; Li XQ; Wang L
    Pathol Res Pract; 2020 Oct; 216(10):153099. PubMed ID: 32853942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.